The oversubscribed round was co-led by Forbion, FMC Ventures, and Corteva Inc.
"SOLASTA Bio has come a long way since we set out on this journey 3 years ago. Having established operations in the UK and US, we’ve now got an international team with outstanding competencies in technology and agribusiness and, importantly, we have developed our unique technology platform to address grower pain points. The results of our field trials have been hugely encouraging, demonstrating high efficacy of biopeptides against target insect pests, as effective or better than standard insecticides. With Series A now secured, it’s time for SOLASTA Bio to kick on to the next level and successfully hit our targets for commercialisation."
The university spin-out has raised over £1m in total funding to develop targeted cancer therapeutics.
"Our technology opens up a new space in oncology drug discovery, to treat a range of malignancies, including rare cancers that currently have no effective treatment options. We are confident that the combined backing of the Development Bank and Start Codon, alongside the universities and M-Sparc, means that we now have the support to fast-track our innovative science into a successful global commercial venture that could help treat cancers."
Balderton Capital and Exor Ventures have led a seed round to help finance clinical trials and expand manufacturing capabilities.
"At SAVA we are tackling preventable illness by building a new operating system for health monitoring. Our microsensor will revolutionise healthcare by making world-leading monitoring technology available to all. With this capital, we can accelerate our goal of creating a new paradigm for healthcare – preventative, personalised and painless."
The investment was led by the Scottish National Investment Bank with backing from Archangel Investors and Par Equity.
"We are excited by the growth and impact potential of iGii, and we are pleased to be invested in the company's future, which includes scaling its products for a global market and bringing more skilled jobs to Stirling."
— Alastair McMillen, Associate Director – Sustainable Places
The seed round was co-led by Octopus Ventures and redalpine to support preclinical candidate selection and pipeline development.
"At ExpressionEdits, we’re revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production"
